Pathology . J Mol Diagn 2006 ; 8 : 412 – 419 . 12. Maxson JE Gotlib J Pollyea DA . Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML . N Engl J Med 2013 ; 368 : 1781 – 1790 . 13. Piazza R Valletta S
Search Results
Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa
David R. Braxton
picture of the molecular landscapes of cancer and many insights into the molecular pathology of cancers are accruing. Genomic databases such as cBioPortal ( www.cbiopartal.org ) 8 are providing access to large-scale genomic data where inferences can be
Richard B. Hostetter, Min Yan, Houman Vaghefi, Kenneth Pennington, and Gary Cornette
higher total doses (60–66 Gy in 30–33 fractions). The advantage of adjuvant therapy is that the final pathology is clearly established. 3 Figure 6 Spindle tumor cells in bundle and fascicles (hematoxylin-eosin stain, original magnification x100
Damien Urban, Danny Rischin, Christopher Angel, Ieta D’Costa, and Benjamin Solomon
Classification of Tumours. Pathology and Genetics of Head and Neck Tumours . Lyon, France : IARC Press ; 2005 . 2. Wang YL Zhu YX Chen TZ . Clinicopathologic study of 1176 salivary gland tumors in a Chinese population: experience of one cancer
Brian Vicuna and Al B. Benson III
: 65 – 69 . 15. Morris E Maughan NJ Forman D Quirke P . Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? – The need for high quality pathology . Gut 2007 ; 56 : 1419 – 1425 . 16. Soreide K Janssen EA
Gregory P. Kalemkerian
only medical and radiation oncology, but also thoracic surgery, pathology, and diagnostic radiology. Another substantial improvement in the NCCN Guidelines for SCLC (and many others) has been the inclusion of “Principles of” sections that provide
Badar M. Mian
biopsies in a population-based screening study: the impact of borderline lesions . Cancer 1999 ; 85 : 145 – 152 . 35 Orozco R O'Dowd G Kunnel B . Observations on pathology trends in 62,537 prostate biopsies obtained from urology private
Louis Burt Nabors
complete all of the prescribed cycles of chemotherapy,” revealed Dr. Nabors. Based on the findings of both RTOG 9402 and EORTC 26951, the adjuvant treatment pathway in the 2015 NCCN Guidelines for CNS Cancers hinges on the pathology results of the
Lori J. Goldstein, Bonnie J. Miller, Nancy Nicotera, and Delinda Pendleton
hand-offs that occur during the intake and registration processes; obtaining patient materials (pathology tissue, radiology films) with complete interpretation in advance of the patient’s first visit; and wherever possible, performance of studies in
Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Nicholas Butowski, Robert A. Fenstermaker, Peter Forsyth, Jona Hattangadi-Gluth, Matthias Holdhoff, Steven Howard, Larry Junck, Thomas Kaley, Priya Kumthekar, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Seema Nagpal, Manjari Pandey, Ian Parney, Katherine Peters, Vinay K. Puduvalli, John Ragsdale III, Jason Rockhill, Lisa Rogers, Chad Rusthoven, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, Christina Tsien, Stephanie Weiss, Patrick Yung Wen, Nicole Willmarth, Mary Anne Bergman, and Anita Engh
Pathology” (see BRAIN-F, pages 1334 and 1335) to provide background and recommendations for histologic characterization and molecular testing for gliomas. This article also describes data from clinical trials with available molecular information that have